---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145153"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:42:32.259220+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaccinex raises ~$2.96M via private placement of 7.9M shares at $0.37428

## Summary
- Sold 7,908,516 shares at $0.37428/share for $2.96M gross proceeds; closed May 15, 2023.
- Proceeds to fund pepinemab development in cancer/neurodegenerative disease and working capital.
- FCMI Parent Co., controlled by chairman Albert D. Friedberg, participated in the offering.
- Shares unregistered; exempt under Rule 506 and Section 4(a)(2); registration rights granted to other investors.

## SEC filing metadata
- accession: 0001193125-23-145153
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312523145153/0001193125-23-145153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312523145153/d464446d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145153
- JSON: https://secwatch.observer/filing/0001193125-23-145153.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145153.txt

## Key facts
- Material Agreements
  VACCINEX, INC. entered into Stock Purchase Agreement with certain accredited investors valued at approximately $2.96 million (effective 2023-05-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $2.96 million
  - Effective: 2023-05-12
  source text: On May 12, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell 7,908,516 shares of common stock of the Company (the “Shares”) at a purchase price of $0.37428 per Share for aggregate gross proceeds of approximately $2.96 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312523145153/0001193125-23-145153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.